Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Pharmadrug Production GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics
Details : Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Pharmadrug Production GmbH
Deal Size : Undisclosed
Deal Type : Acquisition